[ad_1]
US authorities have granted biotech company Regeneron emergency approval for its corona infection agent.
US company REGN-COV2’s experimental antibody cocktail could help avoid hospitalization for coronary patients and thus ease the burden on the health system, Stephen Hahn (60) of the US FDA (local time) said Saturday.
The agent was used in early October to treat US President Donald Trump (74) against his crown infection. Soon after, Regeneron asked the FDA for permission to use its drug in Covid 19 patients with mild to moderate symptoms.
The active ingredient of REGN-COV2 is a combination of two specially developed antibodies that bind to the so-called spike protein of the coronavirus and can thus deform its structure. This is to prevent the coronavirus from attacking human cells. According to Regeneron, the combination of two different antibodies should prevent the Sars-COV2 virus from mutating.
Biotech and pharmaceutical companies around the world are currently working in full swing on developing drugs and vaccines to fight the coronavirus. More recently, the successes of biotech companies Biontech and Moderna in developing a corona vaccine had given hope that the pandemic could be contained. The Mainz-based firm Biontech and its US partner Pfizer applied to the FDA on Friday for emergency approval of their vaccine.
The US is the country most affected by the corona pandemic in the world. In the United States, more than twelve million coronavirus infections have already been detected and more than 255,000 people have died.
.
[ad_2]
Source link
